Five to ten percent of treatment-naive patients in these settings have primary drug resistance, according to data presented at the 2008 International AIDS Conference.
Clearly, one of the most gratifying advances in the global fight against HIV has been the increase in access to antiretroviral therapy (ART). Today, more than 3 million people are receiving ART, with the great majority of them in resource-constrained settings. Most countries have been able to achieve this success by limiting the available treatment options to fixed-dose combinations such as AZT/3TC/nevirapine (Duovir) and d4T/3TC/nevirapine (Triomune). At this year’s International AIDS Conference, investigators described patterns of resistance in these settings, among both treatment-naive and treatment-experienced patients.
Estimates of HIV drug resistance among treatment-naive patients in resource-constrained settings are in the range of 5%…
Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)